Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
BMC Cancer|October 10, 2020
Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trialLucas C Mendez, Andrew J Arifin, Glenn S Bauman, et al.European Journal of Medicinal Chemistry|December 4, 2018
Synthesis and mechanistic studies of diketo acids and their bioisosteres as potential antibacterial agentsPhool Hasan, Vijay K Pillalamarri, Babita Aneja, et al.International Journal of Radiation Oncology, Biology, Physics|August 31, 2019
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized TrialRobert Olson, Suresh Senan, Stephen Harrow, et al.Cureus|January 17, 2020
A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain OligometastasesGeorge Rodrigues, Slav Yartsev, David Roberge, et al.Journal of Neuro-Oncology|April 17, 2016
Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastasesGlenn Bauman, Slav Yartsev, David Roberge, et al.European Urology|August 17, 2021
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Samir Patel, Scott A North, et al.Lancet (London, England)|April 16, 2019
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A Palma, Robert Olson, Stephen Harrow, et al.International Journal of Radiation Oncology, Biology, Physics|June 1, 2022
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term OutcomesStephen Harrow, David A Palma, Robert Olson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2020
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialDavid A Palma, Robert Olson, Stephen Harrow, et al.BMC Cancer|August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialDavid A Palma, Robert Olson, Stephen Harrow, et al.Pageof 4